Abstract: The present invention relates to modified histone proteins for use in promoting coagulation, wherein the modified histone protein has reduced cytotoxicity as compared to a corresponding wild-type histone protein. The invention also relates to said modified histone proteins for use in promoting coagulation in the inhibition of bleeding and in promoting coagulation in a coagulation assay. In addition, the invention relates to a method of promoting coagulation in a subject in need thereof, the method comprising the step of providing the subject with said modified histone proteins. The invention also relates to an expression vector comprising a nucleic acid encoding said modified histone protein.

Abstract: A method for diagnosing and monitoring subjects for hemostatic dysfunction, severe infection and systematic inflammatory response syndrome is provided whereby lipoproteins are examined for abnormalities, particularly for prothrominase enhancement, through quantitative and qualitative analysis.

Abstract: A method for diagnosing a condition of a patient involves the steps of (a) adding one or more reagents to a test sample from a patient, the test samples comprising at least part of a blood sample from the patient, in order to cause formation of a complex comprising at least one acute phase protein at at least one human lipoprotein, while causing substantially no fiber polymerization; (b) measuring the formation of the complex over time so as to derive a time-dependent measurement profile, and (c) determining a slope and/or total change in the time-dependent measurement profile, so as to diagnose a condition of the patient. A greater formation of the complex is correlated to increased probability of death of the patient.

Abstract: Methods for predicting the presence of haemostatic dysfunction in a patient from a time-dependent measurement profile include performing a time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile. The slope of the time-dependent measurement profile is computed prior to clot formation. A biphasic waveform is detected in the time-dependent measurement profile based on the computed slope. The presence of haemostatic dysfunction in the patient is predicted based on the detected biphasic waveform.

Abstract: A method for diagnosing a condition of a patient involves the steps of (a) adding one or more reagents to a test sample from a patient, the test samples comprising at least part of a blood sample from the patient, in order to cause formation of a complex comprising at least one acute phase protein and at least one human lipoprotein, while causing substantially no fiber polymerization; (b) measuring the formation of the complex over time so as to derive a time-dependent measurement profile, and (c) determining a slope and/or total change in the time-dependent measurement profile, so as to diagnose a condition of the patient. A greater formation of the complex is correlated to increased probability of death of the patient.

Abstract: A method is disclosed for predicting the presence of haemostatic dysfunction. At least one time-dependent measurement on an unknown sample is performed and a respective property of the sample is measured over time so as to derive a time-dependent measurement profile. One or more predictor variables, including initial slope, are defined which sufficiently define the data of the time-dependent measurement profile. A model is then derived that represents the relationship between the abnormality and the set of predictor variables. Subsequently, the model is utilized to predict haemostatic dysfunction, such as septicemia or disseminated intravascular coagulation (DIC).

Abstract: Methods for predicting the presence of haemostatic dysfunction in a patient from a time-dependent measurement profile include performing a time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile. The slope of the time-dependent measurement profile is computed prior to clot formation. A biphasic waveform is detected in the time-dependent measurement profile based on the computed slope. The presence of haemostatic dysfunction in the patient is predicted based on the detected biphasic waveform.

Abstract: A method for diagnosing and monitoring subjects for hemostatic dysfunction, severe infection and systematic inflammatory response syndrome is provided whereby lipoproteins are examined for abnormalities, particularly for prothrominase enhancement, through quantitative and qualitative analysis.

Abstract: A method which may be used to determine haemostatic dysfunction in a patient is carried out by (a) adding a reagent to a test sample, wherein the test sample includes at least a component of a blood sample from a patient; and then (b) measuring the formation of a precipitate due to the reaction of the test sample and the reagent, over time so as to derive a time-dependent measurement profile, the reagent forming a precipitate in the test sample without causing substantial fibrin polymerization.

Abstract: A method for diagnosing a condition of a patient involves the steps of (a) adding one or more reagents to a test sample from a patient, the test samples comprising at least part of a blood sample from the patient, in order to cause formation of a complex comprising at least one acute phase protein at at least one human lipoprotein, while causing substantially no fiber polymerization; (b) measuring the formation of the complex over time so as to derive a time-dependent measurement profile, and (c) determining a slope and/or total change in the time-dependent measurement profile, so as to diagnose a condition of the patient. A greater formation of the complex is correlated to increased probability of death of the patient.

Abstract: A method which may be used to determine haemostatic dysfunction in a patient is carried out by (a) adding a reagent to a test sample, wherein the test sample includes at least a component of a blood sample from a patient; and then (b) measuring the formation of a precipitate due to the reaction of the test sample and the reagent, over time so as to derive a time-dependent measurement profile, the reagent forming a precipitate in the test sample without causing substantial fibrin polymerization.